Current through Register Vol. 35, No. 11, June 11, 2024
Section 7.34.3.8 - QUALIFYING DEBILITATING MEDICAL CONDITIONSA.Statutorily-approved conditions: As of the date of promulgation of this rule, specific qualifying debilitating medical conditions, diseases, and treatments ("qualifying conditions") identified in the Lynn and Erin Compassionate Use Act, Subsection B of Section 26-2B-3 NMSA 1978, include: (4) damage to the nervous tissue of the spinal cord, with objective neurological indication of intractable spasticity;(5) seizure disorder, including epilepsy;(6) positive status for human immunodeficiency virus or acquired immune deficiency syndrome;(7) admission into hospice care in accordance with rules promulgated by the department.(8) amyotrophic lateral sclerosis (Lou Gehrig's disease);(10) hepatitis C infection;(11) Huntington's disease;(12) inclusion body myositis;(13) inflammatory autoimmune-mediated arthritis: each individual applying to the program for enrollment shall submit medical records that confirm the diagnosis of inflammatory autoimmune-mediated arthritis;(14) intractable nausea/vomiting;(15) obstructive sleep apnea;(16) painful peripheral neuropathy: application to the medical cannabis program shall be accompanied by medical records that confirm the objective presence of painful peripheral neuropathy;(17) Parkinson's disease;(18) post-traumatic stress disorder (PTSD): each individual applying to the program for enrollment shall submit medical records that confirm a diagnosis of PTSD meeting the diagnostic criteria of the current diagnostic and statistical manual of mental disorders;(19) severe chronic pain:(a) objective proof of the etiology of the severe chronic pain shall be included in the application; and(b) a practitioner familiar with the patient's chronic pain shall provide written certification that the patient has an unremitting severe chronic pain condition;(20) severe anorexia/cachexia;(21) spasmodic torticollis (cervical dystonia); andB.Department-approved conditions: The department finds that the following additional qualifying conditions result in pain, suffering, or debility for which there is credible evidence that the medical use of cannabis could be of benefit, through the alleviation of symptoms, and the department accordingly approves these conditions as qualifying debilitating medical conditions for the participation of a qualified patient or primary caregiver in the medical cannabis program. The department-approved conditions include: (1) autism spectrum disorder;(4) spinal muscular atrophy;(7) such other conditions as the secretary may approve.C.Additional application requirements: A patient shall submit with the patient's application a written certification from the patient's practitioner which shall attest:(1) to the diagnosis of the medical condition;(2) that the condition is debilitating; and(3) that potential risks and benefits of the use of medical cannabis for the condition have been discussed with the patient, in accordance with this rule; a patient who applies on the basis of having a department-approved condition may also be required to satisfy additional eligibility criteria, as specified in this rule.D.Annual written certification requirement: Pursuant to the Lynn and Erin Compassionate Use Act, Section 26-2B-7.1 NMSA 1978, in order to remain eligible for participation in the medical cannabis program, a qualified patient shall submit annually to the department, and at least 30 calendar days prior to the annual certification date printed on their card, a statement from a practitioner on a department approved form. The annual written certification shall be attested by the certifying practitioner no more than 90 days prior to submission of the certification to the department. The certification shall indicate the following:(1) the practitioner has examined the qualified patient during the preceding 12 months;(2) the qualified patient continues to have a debilitating medical condition; and(3) the practitioner believes that the potential health benefits of the medical use of cannabis would likely outweigh the health risks for the qualified patient.E.Modification or removal of department-approved conditions: The secretary may remove or modify a department-approved condition only if the secretary determines, on the basis of substantial credible medical and scientific evidence, and after an opportunity for review of the proposed removal or modification by the medical advisory board, that the use of cannabis by patients who have the approved condition would more likely than not result in substantial harm to the patients' health.7.34.3.8 NMAC - N, 12/30/2010, Amended by New Mexico Register, Volume XXVI, Issue 04, February 27, 2015, eff. 2/27/2015, Amended by New Mexico Register, Volume XXVII, Issue 04, February 29, 2016, eff. 2/29/2016, Amended by New Mexico Register, Volume XXX, Issue 16, August 27, 2019, eff. 8/27/2019, Amended by New Mexico Register, Volume XXXIII, Issue 04, February 22, 2022, eff. 2/22/2022